281 related articles for article (PubMed ID: 32043244)
1. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
Reid J; Rana K; Niman S; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
Am J Cardiovasc Drugs; 2020 Oct; 20(5):419-429. PubMed ID: 32043244
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
3. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
4. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Yandrapalli S; Malik A; Horblitt A; Pemmasani G; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(5):219-235. PubMed ID: 32271194
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
7. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms.
Li W; Yu K; Sun S
Pharmazie; 2020 Jun; 75(6):224-229. PubMed ID: 32539914
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
9. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
[TBL] [Abstract][Full Text] [Related]
10. Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.
Oikonomou E; Xenou M; Zakynthinos GE; Tsaplaris P; Lampsas S; Bletsa E; Gialamas I; Kalogeras K; Goliopoulou A; Gounaridi MI; Pesiridis T; Tsatsaragkou A; Vavouranakis M; Siasos G; Tousoulis D
Curr Pharm Des; 2023; 29(23):1844-1862. PubMed ID: 37403390
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
[TBL] [Abstract][Full Text] [Related]
12. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
Dey AK; Groenendyk J; Mehta NN; Gourgari E
Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
14. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
15. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.
Nelson AJ; Harrington JL; Kolkailah AA; Pagidipati NJ; McGuire DK
Heart Fail Clin; 2022 Oct; 18(4):597-607. PubMed ID: 36216489
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
Chilton RJ
Diabetes Obes Metab; 2020 Jan; 22(1):16-29. PubMed ID: 31407866
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
[TBL] [Abstract][Full Text] [Related]
19. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
20. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
Deerochanawong C; Chan SP; Matawaran BJ; Sheu WH; Chan J; Man NH; Suastika K; Khoo CM; Yoon KH; Luk A; Mithal A; Linong J
Diabetes Obes Metab; 2019 Nov; 21(11):2354-2367. PubMed ID: 31264765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
